TriSalus Life Sciences Conference Call Summary Company Overview - **Company**: TriSalus Life Sciences (NasdaqGM: TLSI) - **Focus**: Improving drug delivery to pancreatic, liver, and solid tumors, with a specific emphasis on a drug called nelitolimod, an immunotherapeutic aimed at reversing immunosuppression in tumors [2][3] Industry Insights - **Uterine Fibroids**: The call highlighted uterine fibroid embolization as a preferable alternative to surgery for patients suffering from uterine fibroids [2][10] - **Interventional Radiology (IR)**: The field has evolved significantly, with IR now recognized as a primary specialty in medicine, performing minimally invasive procedures using image guidance [12] Key Technology and Innovations - **Pressure-Enabled Drug Delivery**: TriSalus's technology modulates pressure and flow to enhance therapeutic delivery to tumors while minimizing exposure to normal tissues [3][5] - **TriNav Infusion System**: A proprietary system designed to improve the delivery of therapeutic agents, particularly in uterine artery embolization [8][10] - **Smart Valve Technology**: This technology allows for better perfusion of drugs into tumors by opening collapsed vessels and enhancing blood flow [5][6] Clinical Evidence and Outcomes - **Uterine Artery Embolization (UAE)**: - UAE is effective for treating uterine fibroids and adenomyosis, providing significant symptomatic relief and a minimally invasive option compared to traditional surgical methods [16][19] - Clinical data showed that UAE is as effective as surgical alternatives, with a slightly higher re-intervention rate [19] - A study indicated a 100% technical and clinical success rate in patients using the TriNav catheter, with significant reductions in heavy menstrual bleeding and pain scores [26][27] Market Dynamics - **Awareness and Education**: There is a lack of awareness among patients and healthcare providers regarding UAE, with many women unaware of this treatment option [17][50] - **Referral Pathways**: Improved collaboration between interventional radiologists and gynecologists is essential to enhance patient access to UAE [50][53] - **Cost-Effectiveness**: The TriNav technology has been shown to be cost-saving due to reduced complications and improved therapeutic delivery, which is appealing to payers [65] Future Directions - **Patient Education Initiatives**: TriSalus plans to enhance patient education through social media and direct outreach to improve awareness of UAE [55][56] - **Research and Data Publication**: Ongoing efforts to publish clinical data supporting the efficacy of TriSalus's technologies will help influence treatment decisions among patients and providers [58] Conclusion TriSalus Life Sciences is positioned to make significant advancements in the treatment of uterine fibroids and solid tumors through innovative drug delivery technologies and a focus on patient education and awareness. The company aims to bridge the gap between interventional radiology and gynecology to improve patient outcomes and expand the adoption of minimally invasive procedures.